CoQ10 is a key mitochondrial antioxidant, and circulating levels are often reduced in people with chronic kidney disease and chronic heart failure, where deficiency is linked to greater oxidative stress and poorer organ function. In CKD cohorts, lower CoQ10 levels correlate with increased cardiovascular risk, and supplementation has been reported to improve markers such as proteinuria, mitochondrial function, and oxidative stress, with some studies suggesting better preservation of kidney function over time. In patients with chronic heart failure, trials such as Q-SYMBIO have shown that CoQ10 supplementation can improve cardiac function parameters and significantly reduce major adverse cardiovascular events, cardiovascular mortality, and heart‑failure–related hospitalizations. This medication is commonly used for Diabetes.
Xu Y, Liu J, Han E, Wang Y, Gao J. Efficacy of coenzyme Q10 in patients with chronic kidney disease: protocol for a systematic review. BMJ Open. 2019 May 14;9(5):e029053. Bakhshayeshkaram M, Lankarani KB, Mirhosseini N, Tabrizi R, Akbari M, Dabbaghmanesh MH, Asemi Z. The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Curr Pharm Des. 2018;24(31):3710-3723. Di Lorenzo A, Iannuzzo G, Parlato A, Cuomo G, Testa C, Coppola M, D'Ambrosio G, Oliviero DA, Sarullo S, Vitale G, Nugara C, Sarullo FM, Giallauria F. Clinical Evidence for Q10 Coenzyme Supplementation in Heart Failure: From Energetics to Functional Improvement. J Clin Med. 2020 Apr 27;9(5):1266. DiNicolantonio JJ, Bhutani J, McCarty MF, O'Keefe JH. Coenzyme Q10 for the treatment of heart failure: a review of the literature. Open Heart. 2015;2:e000326.
Some side effects may be linked to nutrient depletion caused by this medication.
Long term treatment with Biguanides, such as Metformin or Metformin combinations with other drugs, are found in research to reduce vitamin B12 absorption due to it hindering the activity of a calcium-dependent mechanism. Insufficient levels of vitamin B12 can lead to higher circulating homocysteine levels and the elevated risk of neurological problems and cardiovascular diseases.
Biguanide (anti-diabetic) drugs have been found in scientific evidence to decrease serum levels of coenzyme Q10. Type 2 diabetes can increase oxidative stress in the body, weakening its defenses and potentially harming cells. CoQ10, a powerful antioxidant, plays a crucial role in protecting cells from this damage. CoQ10 supplementation may help restore these levels, potentially improving mitochondrial function and protecting the kidneys from damage.
Research has shown that anti-diabetic Biguanide drugs may reduce folic acid absorption. Folic acid is a powerful antioxidant and low levels make the body more susceptible to oxidative stress, which can damage enzymes involved in homocysteine metabolism, and subsequently increase its accumulation. Elevated levels of homocysteine (hyperhomocysteinemia) are a risk factor for various health problems including cardiovascular diseases, neurological problems, osteoporosis, and vision problems.
Biguanides, such as Metformin or Metformin combinations with other drugs, may contribute to reduced levels of thiamine (vitamin B1) in end-stage renal failure patients. Research has found metformin encephalopathy present in patients on hemodialysis for end-stage diabetic renal failure (ESRD). Patients with ESRD should consider having thiamine (vitamin B1) status monitored and supplementing with thiamine when levels are insufficient or deficient.